Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRC 54276 in advanced solid tumors and lymphomas
NCT05878691Phase 1Active, not recruiting
- Sponsor
- Glenmark Specialty
- Start
- Jun 2022
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, open-label trial of GRC 54276 in solid tumor (advanced stage) and lymphoma (3 arms), sponsored by Glenmark Specialty. Primary endpoints: Dose Limiting Toxicities at 18 weeks, Incidence of Treatment-Emergent Adverse Events and Serious Adverse Events at 120 days and 4 more. Started Jun 2022; status: active, not recruiting.
02
Drugs
GRC 54276
03
Conditions
solid tumor (advanced stage)lymphoma
Beyond the preview
Go deeper on NCT05878691.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05878691.